Asofarma de México S.A de C.V.

Quick facts

Phase 3 pipeline

• CLA (Clarithro+Lanso+Amoxi) · Gastroenterology / Infectious Disease
  CLA is a triple-therapy combination that eradicates Helicobacter pylori through dual antibiotic action (clarithromycin and amoxicillin) plus acid suppression (lansoprazole).
• PLA (Panto+Levoflox+Azithro) · Gastroenterology / Infectious Disease
  PLA is a triple-agent combination that reduces gastric acid (pantoprazole), inhibits bacterial DNA gyrase (levofloxacin), and suppresses protein synthesis (azithromycin) to treat infections and acid-related disorders.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Asofarma de México S.A de C.V. portfolio CI brief
• Asofarma de México S.A de C.V. pipeline updates RSS